NewsBenzingaGuggenheim bekräftigt „Buy“ für Rapport Therapeutics und erhöht das Kursziel auf 70 US-Dollar Guggenheim bekräftigt „Buy“ für Rapport Therapeutics und erhöht das Kursziel auf 70 US-Dollar Benzinga 2026.10.21 13:30 (GMT+0) Open on Benzinga Other news 'Trump Grows Frustrated With Vance Over Iran War Critique'- New York Times Why Is Salesforce Stock Falling on Wednesday? This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Ford Ships First Battery Cells from Michigan Plant for Fathom Electric Pickup; Key Milestone for Ford Energy Bill Ackman Says Believes Board Not Acting In Best Interest Of Shareholders Nor In A Manner Consistent With Their Fiduciary Duties; Should Have Slept On Decision To Replace Jensen Huang And Met Again The Day After To Discuss The Facts Crude Oil Down Over 4%; Target Earnings Top Views
Ford Ships First Battery Cells from Michigan Plant for Fathom Electric Pickup; Key Milestone for Ford Energy
Bill Ackman Says Believes Board Not Acting In Best Interest Of Shareholders Nor In A Manner Consistent With Their Fiduciary Duties; Should Have Slept On Decision To Replace Jensen Huang And Met Again The Day After To Discuss The Facts